Other research analysts also recently issued reports about the company. Wedbush restated a buy rating and set a $50.00 price objective on shares of Liquidia Technologies in a research report on Friday, June 28th. Zacks Investment Research downgraded Liquidia Technologies from a buy rating to a hold rating in a research report on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Liquidia Technologies currently has an average rating of Buy and a consensus price target of $31.80.
Shares of Liquidia Technologies stock traded down $0.45 during trading on Thursday, hitting $6.35. 27,073 shares of the company were exchanged, compared to its average volume of 38,519. The company has a debt-to-equity ratio of 0.46, a current ratio of 5.57 and a quick ratio of 5.57. Liquidia Technologies has a fifty-two week low of $6.27 and a fifty-two week high of $38.46. The stock has a market cap of $136.28 million and a PE ratio of -0.85. The stock has a 50 day moving average of $7.99.
A number of hedge funds have recently added to or reduced their stakes in LQDA. Marshall Wace North America L.P. purchased a new stake in Liquidia Technologies in the 1st quarter worth approximately $1,881,000. OZ Management LP purchased a new stake in Liquidia Technologies in the 1st quarter worth approximately $1,138,000. Millennium Management LLC grew its stake in Liquidia Technologies by 91.6% in the 4th quarter. Millennium Management LLC now owns 193,277 shares of the company’s stock worth $4,186,000 after acquiring an additional 92,399 shares during the period. Canaan Partners VIII LLC grew its stake in Liquidia Technologies by 1.3% in the 1st quarter. Canaan Partners VIII LLC now owns 2,597,681 shares of the company’s stock worth $29,561,000 after acquiring an additional 34,378 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Liquidia Technologies in the 4th quarter worth approximately $403,000. 56.37% of the stock is owned by hedge funds and other institutional investors.
Liquidia Technologies Company Profile
Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.
See Also: What is an overbought condition?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.